A simple mail delivery could boost colorectal cancer screening rates
NCT ID NCT05589675
First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time
Summary
This trial tests whether sending a colorectal cancer screening kit directly to people's homes, along with the invitation letter, increases the number of people who get screened. It compares this approach to the standard practice of asking people to visit their doctor to receive the kit. The study involves over 71,000 adults aged 50-74 in France who are new to the national screening program. Some participants also receive a notification one month before the invitation to see if that further boosts participation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Home delivery of a fecal immunochemical test (FIT) kit, with or without a prior notification letter
- What this could lead to
- If mailing the screening kit directly to people's homes increases participation, it could lead to higher colorectal cancer detection rates and save lives through earlier treatment.
- What could go wrong
- The trial is large but only tests a delivery method, not a new treatment. Results may vary by region or population, and even with higher participation, some people may still not complete the test or follow up on positive results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
71,117 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 74 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women and men aged 50 to 74 years old * Living in the study area (Departments of Ardennes, Meurthe-et-Moselle, and Moselle, France) * At moderate risk of colorectal cancer, i.e. eligible to the organised programme and receiving the first invitation of the screening round (not a reminder letter) Exclusion Criteria: * Outside the target age (less than 50 years old, or 75 years and more) * Receiving the reminder letter * At high or very high risk of colorectal cancer
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regional Cancer Screening Coordinating Centre, Ardennes site
Charleville-Mézières, Ardennes, 08000, France
-
Regional Cancer Screening Coordinating Centre, Meurthe-et-Moselle Site
Nancy, Meurthe-et-Moselle, 54500, France
-
Regional Cancer Screening Coordinating Centre, Moselle Site
Metz, Moselle, 57000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers